Aptevo Therapeutics (APVO) EPS (Basic) (2015 - 2026)
Aptevo Therapeutics (APVO) posted EPS (Basic) of -$6.41 for Q1 2026, up 67.42% sequentially from -$19.66 in Q4 2025, and up 99.59% YoY from -$3.21 in Q1 2025.
Aptevo Therapeutics (APVO) EPS (Basic) (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported EPS (Basic) for 12 years, with the latest figure at -$6.41 in Q1 2026.
- Quarterly EPS (Basic) rose 99.59% year-over-year to -$6.41 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.28 (up 99.38% YoY) and the FY2025 annual result came in at -$87.27, up 99.72% from the prior year.
- EPS (Basic) climbed to -$6.41 in Q1 2026 per APVO's latest filing, from -$19.66 in the prior quarter.
- Over five years, EPS (Basic) peaked at $78833.3 in Q1 2023 and troughed at -$8229.5 in Q4 2024.
- A 5-year average of $14717.5 and a median of -$6.41 in 2026 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2024: EPS (Basic) jumped 254.31% in 2023, then slumped 158.98% in 2024.
- Over 5 years, EPS (Basic) stood at $57888.9 in 2022, then plunged by 75.9% to $13952.4 in 2023, then slumped by 158.98% to -$8229.5 in 2024, then soared by 99.76% to -$19.66 in 2025, then jumped by 67.42% to -$6.41 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$6.41, -$19.66, and -$40.13 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 0.18 |
| 10 | Aptevo Therapeutics | 3.19 Mn | -6.60 Mn | - | -5.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.31 |
| Mar 31, 2026 | -6.41 |
| Dec 31, 2025 | -19.66 |
| Sep 30, 2025 | -40.13 |
| Jun 30, 2025 | -168.58 |
| Mar 31, 2025 | -1,581.44 |
| Dec 31, 2024 | -8,229.47 |
| Sep 30, 2024 | -6,440.66 |
| Dec 31, 2023 | 13,952.38 |
| Mar 31, 2023 | 78,833.33 |
| Dec 31, 2022 | 57,888.89 |
| Sep 30, 2022 | 18,333.33 |
| Jun 30, 2022 | 16,555.56 |
| Mar 31, 2022 | 22,250.00 |
| Dec 31, 2021 | 40,625.00 |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 16,500.00 |
| Mar 31, 2021 | 51,750.00 |
| Dec 31, 2020 | -2.44 Mn |
| Sep 30, 2020 | 26,166.67 |